Millennium Post (Kolkata)

Ramping production of Remdesivir to meet demand: Pharma firms

The market situation on supplies is supposed to ease in the next few weeks


NEW DELHI: Several manufactur­ers of Remdesivir, which is being used in Covid treatment, said they have ramped up production of the drug to meet its rising demand across the country.

In view of increased demand for the medicine due to a spike in COVID-19 cases, the Centre on Sunday prohibited the export of Remdesivir injection and its active pharmaceut­ical ingredient­s (API) till the situation in the country improves.

A Zydus Cadila spokespers­on said: “The current spike in COVID-19 cases has led to a higher demand of Remdesivir. We are currently producing Remdesivir at three of our facilities. To cater to the demand, we have ramped up our production from the earlier 5-6 lakh vials a month to 10-12 lakh vials a month, which we will scale towards 20 lakh vials a month.

In a few weeks, the supply situation will be a far more stable one, the company said.

In similar vein, Dr Reddy’s Laboratori­es said it is making every effort to ensure that its Remdesivir reaches as many patients in India, as possible.

“We are ramping up production and are also bringing to market a liquid product that is faster to make and supply. We have also reduced our MRP by 50 per cent so that price is not a barrier to access, and a much larger number of patients can access it,” Dr Reddy’s said in a statement.

The company expects the market situation on supplies to ease in the next few weeks, it added.

“We will continue in our endeavour to make medicines available wherever they are required, and whenever they are required,” Dr Reddy’s said.

Rakesh Bamzai, president — India, Emerging Asia and Access Markets and Commercial Expansion and Biosimilar­s — Emerging Markets, Viatris (formerly called Mylan), said: “We are closely partnering with the government to meet the patient needs in India and ensure access to this critical medicine.”

Drug firm Sun Pharmaceut­ical Industries said it, in collaborat­ion with Syngene, is increasing capacity for Remdesivir to fulfill the increase in demand.

“Sun Pharma has already increased the production and is now manufactur­ing Remdesivir at two plants. The decision to add one more manufactur­ing site was taken recently to help boost our production. We are continuous­ly monitoring the situation and working relentless­ly to ensure patients across India get access to COVID-19 medicines,” a Sun Pharma spokespers­on said.

The company is manufactur­ing and distributi­ng Remdesivir in India in partnershi­p with Syngene, the spokespers­on added.

Pharma firm Cipla has also said it has significan­tly increased the production of Remdesivir from the last wave of the pandemic.

 ?? FILE PHOTO ?? People gather outside Zydus Hospital in Ahmedabad to purchase Remdesivir injections
FILE PHOTO People gather outside Zydus Hospital in Ahmedabad to purchase Remdesivir injections

Newspapers in English

Newspapers from India